LEO PHARMA A/S: Financial statements 2019
CVR: 56759514
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
LEO PHARMA A/S (CVR 56759514) has filed annual accounts for 2019. In 2019, the company reported revenue of DKK 10,805,000,000 and a net result of DKK -1,287,000,000 compared with DKK 1,258,000,000 the year before. That is an increase of 3.8% compared with the year before. The profit margin was -11.9%. Equity in the 2019 report amounted to DKK 8,088,000,000. The solvency ratio was 32.7%.
- Revenue
- DKK 10,805,000,000
- Gross Profit
- DKK 7,455,000,000
- Profit/Loss
- DKK -1,287,000,000
- Equity
- DKK 8,088,000,000
- Total Assets
- DKK 24,760,000,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 10.8 mia. | 7.5 mia. | -1.3 mia. | 8.1 mia. | - |
| 2018 | 10.4 mia. | 7.4 mia. | 1.3 mia. | 9.5 mia. | - |
| 2017 | 10.5 mia. | 7.5 mia. | 1.4 mia. | 8.3 mia. | - |
| 2016 | 7.4 mia. | 2.7 mia. | 743 mio. | 25.2 mia. | 5170 |
| 2015 | 6.9 mia. | 2 mia. | 645 mio. | 25.3 mia. | 4813 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of November 13, 2019, Jane Maria Birgitta Stymne Göransson has joined the board of directors of LEO PHARMA A/S.
As of August 1, 2019, Catherine Thérése Jeanne Mazzacco is registered as adm. dir. of LEO PHARMA A/S.
As of July 31, 2019, Gitte Pugholm Aabo has stepped down as adm. dir. of LEO PHARMA A/S.
LEO PHARMA A/S has published its annual report for 2018. Revenue came to DKK 10,410,000,000, and the net result was DKK 1,258,000,000.
As of February 26, 2019, Anders Ekblom has joined the board of directors of LEO PHARMA A/S.
As of February 26, 2019, Olivier Bohuon has joined the board of directors of LEO PHARMA A/S.
As of February 26, 2019, Jukka Pekka Pertola has left the board of directors of LEO PHARMA A/S.
As of February 26, 2019, John Robert Weeks has left the board of directors of LEO PHARMA A/S.
As of February 25, 2019, Laurids Bonne Bjørnshauge has joined the board of directors of LEO PHARMA A/S.
As of February 25, 2019, Irene Anett Jonassen has left the board of directors of LEO PHARMA A/S.
About LEO PHARMA A/S
LEO PHARMA A/S is a Danish company of the type Aktieselskab based in Ballerup, founded in 1962. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named LØVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB. The management consists of Christophe Dominique Luc Charles Bourdon and Philip Harald Eickhoff. The board consists of Jesper Brandgaard (chair), Paul Olivier Marie Navarre, Peter Helt Jacobsen Haahr and Aino Anna Liisa Hurme. The company is owned by LEO Holding A/S and Cidron Savanna 4 SARL. The company has 1,047 employees (2026). In 2025, the company reported revenue of DKK 13,499,000,000 and a net result of DKK 2,489,000,000 compared with DKK -1,776,000,000 the year before. Equity in the 2025 report amounted to DKK 5,262,000,000.